Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2026)

Royalty Pharma has reported Other Non Operating Income for 8 years, with the latest figure at -$2.2 million in Q1 2026.

• Quarterly Other Non Operating Income rose 28.12% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.1 million (down 173.78% YoY) and the FY2025 annual result came in at -$14.3 million, down 139.15% from the prior year.
• Other Non Operating Income grew to -$2.2 million in Q1 2026 per RPRX's latest filing, from -$15.3 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $6.0 million in Q2 2024 and troughed at -$112.3 million in Q4 2022.
• A 5-year average of -$11.2 million and a median of -$2.1 million in 2025 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2024: Other Non Operating Income plunged 867.29% in 2022, then surged 449.95% in 2024.
• Over 5 years, Other Non Operating Income stood at -$112.3 million in 2022, then surged by 98.48% to -$1.7 million in 2023, then slumped by 427.24% to -$9.0 million in 2024, then tumbled by 70.54% to -$15.3 million in 2025, then soared by 85.66% to -$2.2 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$2.2 million, -$15.3 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.